Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atea Pharmaceuticals (AVIR) Net Cash Flow (2020 - 2022)

Atea Pharmaceuticals has reported Net Cash Flow over the past 3 years, most recently at $11.9 million for Q4 2022.

  • Quarterly results put Net Cash Flow at $11.9 million for Q4 2022, up 115.86% from a year ago — trailing twelve months through Dec 2022 was -$576.0 million (down 573.39% YoY), and the annual figure for FY2025 was $31.0 million, up 139.2%.
  • Net Cash Flow for Q4 2022 was $11.9 million at Atea Pharmaceuticals, up from -$508.1 million in the prior quarter.
  • Over the last five years, Net Cash Flow for AVIR hit a ceiling of $744.7 million in Q4 2020 and a floor of -$508.1 million in Q3 2022.
  • Median Net Cash Flow over the past 3 years was -$13.4 million (2020), compared with a mean of $13.9 million.
  • Biggest five-year swings in Net Cash Flow: skyrocketed 324.79% in 2021 and later plummeted 2271.42% in 2022.
  • Atea Pharmaceuticals' Net Cash Flow stood at $744.7 million in 2020, then plummeted by 110.11% to -$75.3 million in 2021, then soared by 115.86% to $11.9 million in 2022.
  • The last three reported values for Net Cash Flow were $11.9 million (Q4 2022), -$508.1 million (Q3 2022), and -$21.1 million (Q2 2022) per Business Quant data.